Quinn Opportunity Partners adds St. Jude Medical (STJ) to its portfolio

St. Jude Medical (STJ) : Quinn Opportunity Partners added new position in St. Jude Medical during the most recent quarter end. The investment management firm now holds 159,243 shares of St. Jude Medical which is valued at $12,495,798 , the company said in a statement filed on Nov 14, 2016 with the SEC.St. Jude Medical makes up approximately 4.24% of Quinn Opportunity Partners’s portfolio.

Other Hedge Funds, Including , Two Sigma Securities reduced its stake in STJ by selling 118 shares or 2.22% in the most recent quarter. The Hedge Fund company now holds 5,189 shares of STJ which is valued at $407,181. St. Jude Medical makes up approx 0.14% of Two Sigma Securities’s portfolio.Atlantic Trust Group boosted its stake in STJ in the latest quarter, The investment management firm added 18,475 additional shares and now holds a total of 47,410 shares of St. Jude Medical which is valued at $3,755,346. St. Jude Medical makes up approx 0.03% of Atlantic Trust Group’s portfolio.California Public Employees Retirement System reduced its stake in STJ by selling 40,800 shares or 5.46% in the most recent quarter. The Hedge Fund company now holds 706,401 shares of STJ which is valued at $56,102,367. St. Jude Medical makes up approx 0.09% of California Public Employees Retirement System’s portfolio.

St. Jude Medical closed down -0.2 points or -0.25% at $80.02 with 23,00,482 shares getting traded on Monday. Post opening the session at $80.07, the shares hit an intraday low of $79.87 and an intraday high of $80.27 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, St. Jude Medical reported $0.99 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Oct 19, 2016. Analyst had a consensus of $1.01. The company had revenue of $1499.00 million for the quarter, compared to analysts expectations of $1498.08 million. The company’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.97 EPS.

St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

St. Jude Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on St. Jude Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.